Active plasma cell leukemia

Amyloidosis

Stem cell transplant with 12 weeks prior to enrollment, or active GVHD

POEMS syndrome

Any active uncontrolled bacterial, fungal, or viral infection

Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment

Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)

Sub-Study A Only: Previous treatment with BCMA bispecific antibody

Sub-Study B Only: Previous treatment with BCMA directed therapy

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma